Login to Your Account



Immune Design's potential clear as 'GLAAS' in $168M Sanofi deal

By Marie Powers
Staff Writer

Thursday, August 7, 2014
On the heels of its initial public offering (IPO), Immune Design Corp. lured Sanofi SA to an exclusive discovery, development and commercialization license valued at up to $168 million plus an undisclosed up-front payment for therapeutic agents targeting an unspecified food allergy.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription